C
Colleen A. Lawton
Researcher at Medical College of Wisconsin
Publications - 221
Citations - 14959
Colleen A. Lawton is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 57, co-authored 205 publications receiving 13816 citations. Previous affiliations of Colleen A. Lawton include University of Saskatchewan & Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Miljenko V. Pilepich,Kathryn Winter,Colleen A. Lawton,Robert E. Krisch,Harvey B. Wolkov,Benjamin Movsas,Eugen B. Hug,Sucha O. Asbell,David J. Grignon +8 more
TL;DR: In a population of patients with unfavorable prognosis carcinoma of the prostate, androgen suppression applied as an adjuvant after definitive RT was associated not only with a reduction in disease progression but in a statistically significant improvement in absolute survival.
Journal ArticleDOI
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
Miljenko V. Pilepich,Kathryn Winter,Madhu John,John B. Mesic,William T. Sause,P. Rubin,Colleen A. Lawton,Mitchell Machtay,David J. Grignon +8 more
TL;DR: In patients with Gleason score 2--6 carcinoma of the prostate, a short course of androgen ablation administered before and during radiotherapy has been associated with a highly significant improvement in local control, reduction in disease progression, and overall survival.
Journal ArticleDOI
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
Gerald E. Hanks,Thomas F. Pajak,Arthur T. Porter,David J. Grignon,Harmart Brereton,Varagur Venkatesan,Eric M. Horwitz,Colleen A. Lawton,Seth A. Rosenthal,Howard M. Sandler,William U. Shipley +10 more
TL;DR: The RTOG 92-02 trial supports the addition of LT adjuvant AD to STAD with RT for T2c-4 PC and in the exploratory subset analysis of patients with Gleason scores 8 to 10, LT adjUvant AD resulted in a survival advantage.
Journal ArticleDOI
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
Eric M. Horwitz,Kyounghwa Bae,Gerald E. Hanks,Arthur T. Porter,David J. Grignon,Harmar D. Brereton,Varagur Venkatesan,Colleen A. Lawton,Seth A. Rosenthal,Howard M. Sandler,William U. Shipley +10 more
TL;DR: A survival advantage for LTAD + RT in the treatment of locally advanced tumors with a Gleason score of 8 to 10 suggests that this should be the standard of treatment for these high-risk patients.
Journal ArticleDOI
Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
Mack Roach,Kyounghwa Bae,Joycelyn L. Speight,Harvey B. Wolkov,P. Rubin,R. Jeffrey Lee,Colleen A. Lawton,Richard K. Valicenti,David J. Grignon,Miljenko V. Pilepich +9 more
TL;DR: The addition of 4 months of ADT to EBRT appears to have a dramatic impact on clinically meaningful end points in men with locally advanced disease with no statistically significant impact on the risk of fatal cardiac events.